SAN DIEGO, July 10 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus on obesity, today announced the appointment of Heather Turner, J.D. as Vice President and General Counsel. Ms. Turner joins Orexigen from Conor Medsystems, LLC (previously Conor Medsystems, Inc.), in Menlo Park, CA. where most recently she served as Associate General Counsel - Corporate.
Gary Tollefson, M.D., Ph.D., President and CEO of Orexigen, noted: “The addition of the General Counsel position reflects the continued maturing of Orexigen as a newly public entity. Heather’s extensive knowledge of corporate law and experience with financing and strategic transactions will be an excellent complement to our senior management team. We are delighted to have her on board.”
Prior to her work at Conor Medsystems, Ms. Turner had been an Associate at Cooley Godward Kronish LLP (formerly Cooley Godward LLP). Ms. Turner has extensive experience involving public reporting, compliance and disclosure issues, as well as broad knowledge and experience in negotiating and structuring commercial relationships including distribution, manufacturing, supply and clinical trial agreements. The position of General Counsel is new at Orexigen.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen’s lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial. Both product candidates take advantage of the Company’s understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.
CONTACTS: OREXIGEN MEDIA INVESTORS Graham Cooper Stephen Gendel Jason Spark 858 436-8600 212 918-4650 619 849-6005
Orexigen(TM) Therapeutics, Inc.
CONTACT: Graham Cooper of Orexigen, +1-858-436-8600; Media: StephenGendel, +1-212-918-4650 for Orexigen(TM) Therapeutics, Inc.; Investors:Jason Spark, +1-619-849-6005 for Orexigen(TM) Therapeutics, Inc.
Web site: http://www.orexigen.com/
